Pseudomonas aeruginosa is included in the World Health Organization’s Bacterial Priority Pathogen List 2024 because of its concerning ability to acquire and develop high levels of antimicrobial resistance. New-in-class antimicrobial options specifically targeting multidrug-resistant (MDR) P. aeruginosa are lacking.
Glox Therapeutics Ltd. has been awarded a share of a £3 million (US$3.7 million) collaborative discovery program launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) syndicate. The syndicate is a cross-sector initiative driven by Medicines Discovery Catapult, Lifearc and Cystic Fibrosis Trust.
Malaria remains a significant global health challenge, causing over 600,000 deaths annually despite existing prevention and treatment measures. Current vaccines and monoclonal antibodies (mAbs) against Plasmodium falciparum, such as RTS,S/AS01 and R21, primarily target the central repeat region of the circumsporozoite protein (CSP) but have shown limited efficacy in completely preventing infection.
The largest analysis to date of patients taking GLP-1 receptor agonists (GLP-1RAs) has investigated their effects on nearly 175 diseases, and found that compared to three other classes of diabetes medications, individuals with a prescription for GLP-1RAs had a reduced risk of 42 diseases, and an increased risk of 19. The findings, which were published Jan. 20, 2025, in Nature Medicine, provide a comprehensive overview of GLP-1RAs’ effects.
Fox Chase Chemical Diversity Center Inc. and University of Pittsburgh have jointly described new proteolysis targeting chimeras (PROTACs) consisting of Nef (HIV-1)-targeting moiety covalently linked to cereblon (CRBN)-binding moiety.
Universidade Nova De Lisboa has disclosed rhenium complexes described as potentially useful for the treatment of cancer and gram-positive bacterial infections.
Immuron Ltd. has signed a new research collaboration agreement with Monash University to develop new therapeutic drug candidates targeting antimicrobial-resistant pathogens. This work will utilize the Immuron technology platform, and the experience of the Biomedicine Discovery Institute research team.
Investigators at The Scripps Research Institute and Rensselaer Polytechnic Institute have designed novel covalent inhibitors of SARS-CoV-2 papain-like protease (PLpro) and assessed their drug properties in preclinical models.
RSS
